Newsfeeds Archive - Spark Newswire

1 minute read

Reviva To Present New Preclinical Efficacy Data On Brilaroxazine In Idiopathic Pulmonary Fibrosis At 2024 ATS International Conference In San Diego, CA, May 17-22, 2024

May 13, 8:06 AM

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system

RVPH

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

May 9, 12:31 PM

Gainers Embecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday’s regular session. The company’s market cap stands…

CCLD

4 minute read

Reviva to Host KOL Event To Discuss Topline Data From Phase 3 RECOVER Trial Of Brilaroxazine In Schizophrenia

By Benzinga Newsdesk

February 6, 9:13 AM

RVPH

4 minute read

Reviva Provides Corporate And Program Updates And Highlights Key Upcoming Milestones

By Benzinga Newsdesk

January 4, 9:35 AM

– Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE) trial, and positive drug-drug interaction data supporting a

RVPH

1 minute read

Movers

12 Health Care Stocks Moving In Friday’s Pre-Market Session

By Benzinga Insights

December 22, 9:07 AM

Gainers Karuna Therapeutics (NASDAQ:KRTX) stock moved upwards by 47.9% to $318.17 during Friday’s pre-market session. The company’s market…

ALVR

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

December 18, 5:31 PM

Gainers Jin Medical International (NASDAQ:ZJYL) stock moved upwards by 72.5% to $175.76 during Monday’s after-market session. The market…

BCAB

1 minute read

Analyst Assessment On Reviva Pharmaceuticals’ Positive Schizophrenia Trial Data – Sees More Than 200% Upside In Stock

By Vandana Singh

October 30, 1:49 PM

Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) shares are surging after the company released topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine signaling modulator in

RVPH

3 minute read

Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

October 30, 1:30 PM

Gainers Miromatrix Medical (NASDAQ:MIRO) shares increased by 217.2% to $3.3 during Monday’s regular session. The current volume of…

ABVC

1 minute read

Could This Be A Breakthrough in Mental Health? Reviva’s Schizophrenia Drug Shows Promising Results In Key Trial

By Vandana Singh

October 30, 11:45 AM

Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) announced the topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine signaling modulator in

RVPH